Elicio Therapeutics (ELTX) Operating Expenses (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Operating Expenses came in at $10.6 million in Q1 2026, down 1.25% YoY from $10.7 million in Q1 2025, and up 19.9% on a QoQ basis from $8.8 million in Q4 2025.
Elicio Therapeutics (ELTX) Operating Expenses (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Operating Expenses data on file, last reported at $10.6 million in Q1 2026.
- Quarterly Operating Expenses fell 1.25% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.6 million (down 17.37% YoY) and the FY2025 annual result came in at $37.7 million, down 16.17% from the prior year.
- Operating Expenses climbed to $10.6 million in Q1 2026, from $8.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $16.1 million in Q1 2022 to a low of $5.8 million in Q3 2022.
- A 5-year average of $9.6 million and a median of $10.1 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses slumped 66.82% — and 2023, when it soared 86.67%.
- Tracing ELTX's Operating Expenses over 5 years: stood at $6.0 million in 2022, then jumped by 57.56% to $9.4 million in 2023, then soared by 43.48% to $13.5 million in 2024, then sank by 34.39% to $8.8 million in 2025, then climbed by 19.9% to $10.6 million in 2026.
- The last three Operating Expenses figures came in at $10.6 million (Q1 2026), $8.8 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - | 10.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.43 Mn |
| Mar 31, 2026 | 10.60 Mn |
| Dec 31, 2025 | 8.84 Mn |
| Sep 30, 2025 | 8.05 Mn |
| Jun 30, 2025 | 10.09 Mn |
| Mar 31, 2025 | 10.74 Mn |
| Dec 31, 2024 | 13.48 Mn |
| Sep 30, 2024 | 10.34 Mn |
| Jun 30, 2024 | 10.92 Mn |
| Mar 31, 2024 | 10.24 Mn |
| Dec 31, 2023 | 9.39 Mn |
| Sep 30, 2023 | 10.77 Mn |
| Jun 30, 2023 | 7.78 Mn |
| Mar 31, 2023 | 7.81 Mn |
| Dec 31, 2022 | 5.96 Mn |
| Sep 30, 2022 | 5.77 Mn |
| Jun 30, 2022 | 6.23 Mn |
| Mar 31, 2022 | 16.13 Mn |
| Dec 31, 2021 | 11.31 Mn |
| Sep 30, 2021 | 17.22 Mn |